28.62SEK+0.85%Mkt Cap: 2.96B SEKP/E: —Last update: 2026-05-13
Hansa Biopharma AB (publ), a biopharmaceutical company, engages in development and commercialization of treatments for patients with rare immunological conditions in Sweden, North America, and rest of Europe. The company…
Industry Peers
Biotechnologyloading…
Indicators:|
Key Statistics
Valuation
P/E (Trailing)—
P/E (Forward)-4.02
PEG—
P/B-10.96
P/S15.52
EV/EBITDA-6.13
EV/Revenue18.28
EPS (TTM)-7.94
EPS (Forward)-7.37
Cash Flow & Leverage
FCF Yield-11.78%
FCF Margin-182.76%
Operating CF-549.17M SEK
CapEx (TTM)—
Net Debt/EBITDA-0.82
Net Debt465.80M SEK
Technical
SMA 5029.32 (-2.4%)
SMA 20032.12 (-10.9%)
Beta1.50
S&P 52W Chg24.23%
Avg Vol (30d)369.96K
Avg Vol (10d)278.52K
Technical Indicators
RSI (14)50.0
MACD-0.3574
MACD Signal-0.6405
MACD Hist.+0.2830
BB Upper30.39 SEK
BB Middle27.84 SEK
BB Lower25.28 SEK
BB Width18.37%
ATR (14)1.340 SEK
Vol Ratio (20d)0.18x
52W Range
22.8229% of range42.98
52W High42.98 SEK
52W Low22.82 SEK
Profitability
Gross Margin62.41%
EBITDA Margin-298.07%
Profit Margin-240.30%
Oper. Margin-411.08%
ROE600.18%
ROA-45.78%
Revenue Growth-47.90%
Earnings Growth—
Balance Sheet
Debt/Equity-10.55
Current Ratio3.63
Quick Ratio3.60
Book Value/Sh-2.7050 SEK
Cash/Share6.647 SEK
Dividends
Fwd Div Rate—
Trail. Div Rate0.0000 SEK
Div. Yield—
5Y Avg Yield—
Payout Ratio0.00%
Ex-Div Date—
Pay Date—
Ownership
Shares Out.99.73M
Float64.40M
Insiders9.80%
Institutions47.54%
Analyst Consensus
Rating1.3 (Strong Buy)
Target (Mean)75.00 SEK
Target Range35.00 SEK – 103.00 SEK
# Analysts7
Company
Market Cap2.96B SEK
Enterprise Value3.48B SEK
Revenue (TTM)190.49M SEK
Gross Profit138.71M SEK
Net Income (TTM)-534.11M SEK
Revenue/Share2.124 SEK
Fiscal Year EndDec 2025
MR QuarterMar 2026
Employees122
Last Price28.62 SEK
CountrySE
SectorHealthcare
IndustryBiotechnology
ISINSE0002148817